bluebird bio Inc. announced a series of changes to its business operating plan on 11 May intended to sustain the business financially amid some development and regulatory delays caused partly by the COVID-19 pandemic. During the company’s first quarter sales and earnings call, bluebird said it would be deferring some commercial plans, prioritizing key R&D programs and has revised the terms of its partnership with Bristol Myers Squibb Co. on the multiple myeloma therapy idecabtagene vicleucel (ide-cel) to monetize some of the value.
At the same time, the company also announced it has reached an agreement with the US Food and Drug Administration on an accelerated approval path for LentiGlobin in sickle cell disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?